Sign In to Follow Application
View All Documents & Correspondence

Copolymer And Medical Material Using Same

Abstract: The purpose of the present invention is to provide: a copolymer that is capable of being immobilized on a base material while maintaining a high antithrombotic property persistently without having to introduce heparin or an anticoagulant drug to the surface thereof; and a medical material using same. Provided is a copolymer that comprises monomer unit A monomer unit B and monomer unit C represented in in chemical formula 1 wherein monomer unit C has a mole fraction of 0.5-40% with respect to the total amount of all constituent monomer units.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
04 April 2019
Publication Number
19/2019
Publication Type
INA
Invention Field
POLYMER TECHNOLOGY
Status
Email
patent@depenning.com
Parent Application
Patent Number
Legal Status
Grant Date
2021-01-29
Renewal Date

Applicants

TORAY INDUSTRIES, INC.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku' Tokyo 103-8666, Japan

Inventors

1. USHIRO, Suguru
c/o Shiga Planto Toray Industries, Inc., 1,- l, Sonoyama l-chome, Otsu-shi, Shiga 520-8558, Japan
2. HAYASHI, Akihiro
c/o Shiga Planto Toray Industries, Inc., 1,-1, Sonoyama l-chome, Otsu-shi, Shiga 520-8558, Japan
3. UENO, Yoshiyuki
c/o Shiga Planto Toray Industries, Inc., 1,-1, Sonoyama l-chome, Otsu-shi, Shiga 520-8558, Japan

Specification

WE CLAIM:
1. A copolymer comprising a monomer unit A, a monomer unit B, and a monomer unit C that are represented by-general formula (I) shown below,
wherein a mole fraction of the monomer unit C based on all monomer units that constitute the copolymer is 0.5 to 40%: [Chemical Formula 1]
wherein RA represents a functional group having an amide bond, RB represents an alkyl or an alkenyl having 2 to 20 carbon atoms, Rc represents an alkyl or an alkenyl in which an arbitrary hydrogen atom is substituted with at least one functional group selected from the group consisting of an amino group, an azido group, an imino group, a carboxy group, an acid chloride group, an acid anhydride group, an aldehyde group, a hydroxyl group, a phosphoric acid group, a thiol group, an isocyanate group, a thioisocyanate group, an epoxy group, a halogenated alkyl

group, a cyano group, a vinyl group, an ethynyl group, a nitro group and a nitroso group, and ionized functional groups thereof (wherein an arbitrary carbon atom in the alkyl or the alkenyl of Rc is optionally substituted with a nitrogen atom, an oxygen atom, or a sulfur atom), and X1, X2, and X3 each represent a hydrogen atom or a methyl group.
2. The copolymer according to claim 1, wherein the monomer unit A is represented by any one of general formulae (II) to (IV) shown below: [Chemical Formula 2]

wherein m represents an integer of 1 to 5.
3. The copolymer according to claim 1 or 2, wherein the monomer unit A, the monomer unit B, and the monomer unit C are randomly arranged.
4. The copolymer according to any one of claims 1 to 3, having a number average molecular weight of 1,000 to 100,000.
5. The copolymer according to any one of claims 1 to 4, wherein Rc is an alkyl group in which an arbitrary hydrogen atom is substituted with at least one functional group selected from an amino group, an isocyanate group, and an epoxy group.
6. A medical material containing the copolymer according to any one of claims 1 to 5, and a base material bonded to the copolymer.

7. The medical material according to claim 6, wherein the base material is made from a polymer .having a repeating unit containing an ester bond in a main chain.
8. The medical material according to claim 6, further comprising a phosphonic acid derivative or a catechol derivative,
wherein the base material is made of a metal,
the copolymer is bonded to the phosphonic acid derivative or the catechol derivative,
the phosphonic acid derivative is bonded to the base material via a phosphonic acid group thereof, and
the catechol derivative is bonded to the base material via a catechol group thereof.
9. A thrombus capture device including the medical material according to any one of claims 6 to 8.
10. The medical material according to claim 6, wherein the base material is made from a polymer a part of which contains a hydroxyl group or a carboxy group introduced therein and in which at least, one hydrogen atom in a main chain is substituted with a chlorine atom, or a polymer a part of which contains a hydroxyl group or a carboxy group introduced therein and that has a siloxane bond in at least

a part thereof, and the copolymer is bonded to the base material via the hydroxyl group or the carboxy group.
11. A blood circuit including the medical material according to claim 10.

Documents

Application Documents

# Name Date
1 201947013667.pdf 2019-04-04
2 201947013667-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [04-04-2019(online)].pdf 2019-04-04
3 201947013667-STATEMENT OF UNDERTAKING (FORM 3) [04-04-2019(online)].pdf 2019-04-04
4 201947013667-PROOF OF RIGHT [04-04-2019(online)].pdf 2019-04-04
5 201947013667-PRIORITY DOCUMENTS [04-04-2019(online)].pdf 2019-04-04
6 201947013667-POWER OF AUTHORITY [04-04-2019(online)].pdf 2019-04-04
7 201947013667-FORM 1 [04-04-2019(online)].pdf 2019-04-04
8 201947013667-Written submissions and relevant documents [15-01-2021(online)].pdf 2021-01-15
8 201947013667-DRAWINGS [04-04-2019(online)].pdf 2019-04-04
9 201947013667-DECLARATION OF INVENTORSHIP (FORM 5) [04-04-2019(online)].pdf 2019-04-04
9 201947013667-Correspondence to notify the Controller [04-01-2021(online)].pdf 2021-01-04
10 201947013667-COMPLETE SPECIFICATION [04-04-2019(online)].pdf 2019-04-04
10 201947013667-FORM 3 [19-11-2020(online)].pdf 2020-11-19
11 201947013667-Annexure [20-10-2020(online)].pdf 2020-10-20
11 201947013667-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [04-04-2019(online)].pdf 2019-04-04
12 201947013667-certified copy of translation [20-10-2020(online)].pdf 2020-10-20
12 Correspondence by Agent_Form1_12-04-2019.pdf 2019-04-12
13 201947013667-CLAIMS [20-10-2020(online)].pdf 2020-10-20
13 201947013667-FORM 3 [09-09-2019(online)].pdf 2019-09-09
14 201947013667-FER_SER_REPLY [20-10-2020(online)].pdf 2020-10-20
14 201947013667-FORM 3 [17-12-2019(online)].pdf 2019-12-17
15 201947013667-FORM 18 [20-04-2020(online)].pdf 2020-04-20
15 201947013667-FORM 3 [20-10-2020(online)].pdf 2020-10-20
16 201947013667-FER.pdf 2020-07-29
16 201947013667-FORM-26 [20-10-2020(online)].pdf 2020-10-20
17 201947013667-Information under section 8(2) [20-10-2020(online)].pdf 2020-10-20
17 201947013667-OTHERS [20-10-2020(online)].pdf 2020-10-20
18 201947013667-Information under section 8(2) [20-10-2020(online)].pdf 2020-10-20
18 201947013667-OTHERS [20-10-2020(online)].pdf 2020-10-20
19 201947013667-FER.pdf 2020-07-29
19 201947013667-FORM-26 [20-10-2020(online)].pdf 2020-10-20
20 201947013667-FORM 18 [20-04-2020(online)].pdf 2020-04-20
20 201947013667-FORM 3 [20-10-2020(online)].pdf 2020-10-20
21 201947013667-FER_SER_REPLY [20-10-2020(online)].pdf 2020-10-20
21 201947013667-FORM 3 [17-12-2019(online)].pdf 2019-12-17
22 201947013667-CLAIMS [20-10-2020(online)].pdf 2020-10-20
22 201947013667-FORM 3 [09-09-2019(online)].pdf 2019-09-09
23 201947013667-certified copy of translation [20-10-2020(online)].pdf 2020-10-20
23 Correspondence by Agent_Form1_12-04-2019.pdf 2019-04-12
24 201947013667-Annexure [20-10-2020(online)].pdf 2020-10-20
24 201947013667-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [04-04-2019(online)].pdf 2019-04-04
25 201947013667-COMPLETE SPECIFICATION [04-04-2019(online)].pdf 2019-04-04
25 201947013667-FORM 3 [19-11-2020(online)].pdf 2020-11-19
26 201947013667-Correspondence to notify the Controller [04-01-2021(online)].pdf 2021-01-04
26 201947013667-DECLARATION OF INVENTORSHIP (FORM 5) [04-04-2019(online)].pdf 2019-04-04
27 201947013667-DRAWINGS [04-04-2019(online)].pdf 2019-04-04
27 201947013667-Written submissions and relevant documents [15-01-2021(online)].pdf 2021-01-15
28 201947013667-FORM 1 [04-04-2019(online)].pdf 2019-04-04
28 201947013667-Retyped Pages under Rule 14(1) [15-01-2021(online)].pdf 2021-01-15
29 201947013667-POWER OF AUTHORITY [04-04-2019(online)].pdf 2019-04-04
29 201947013667-2. Marked Copy under Rule 14(2) [15-01-2021(online)].pdf 2021-01-15
30 201947013667-PRIORITY DOCUMENTS [04-04-2019(online)].pdf 2019-04-04
30 201947013667-PatentCertificate29-01-2021.pdf 2021-01-29
31 201947013667-PROOF OF RIGHT [04-04-2019(online)].pdf 2019-04-04
31 201947013667-IntimationOfGrant29-01-2021.pdf 2021-01-29
32 201947013667-STATEMENT OF UNDERTAKING (FORM 3) [04-04-2019(online)].pdf 2019-04-04
32 201947013667-US(14)-HearingNotice-(HearingDate-06-01-2021).pdf 2021-10-18
33 201947013667-RELEVANT DOCUMENTS [24-09-2022(online)].pdf 2022-09-24
33 201947013667-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [04-04-2019(online)].pdf 2019-04-04
34 201947013667-RELEVANT DOCUMENTS [30-09-2023(online)].pdf 2023-09-30
34 201947013667.pdf 2019-04-04

Search Strategy

1 2020-07-2012-12-18E_20-07-2020.pdf

ERegister / Renewals

3rd: 13 Feb 2021

From 20/09/2019 - To 20/09/2020

4th: 13 Feb 2021

From 20/09/2020 - To 20/09/2021

5th: 02 Aug 2021

From 20/09/2021 - To 20/09/2022

6th: 12 Aug 2022

From 20/09/2022 - To 20/09/2023

7th: 10 Aug 2023

From 20/09/2023 - To 20/09/2024

8th: 06 Aug 2024

From 20/09/2024 - To 20/09/2025

9th: 31 Jul 2025

From 20/09/2025 - To 20/09/2026